These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 21861843

  • 21. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke.
    Castellanos M, Leira R, Serena J, Blanco M, Pedraza S, Castillo J, Dávalos A.
    Stroke; 2004 Jul; 35(7):1671-6. PubMed ID: 15166391
    [Abstract] [Full Text] [Related]

  • 22. Predictors for hemorrhagic transformation with intravenous tissue plasminogen activator in acute ischemic stroke.
    Moriya Y, Takahashi W, Kijima C, Yutani S, Iijima E, Mizuma A, Honma K, Uesugi T, Ohnuki Y, Nagata E, Yanagimachi N, Takizawa S.
    Tokai J Exp Clin Med; 2013 Apr 20; 38(1):24-7. PubMed ID: 23564572
    [Abstract] [Full Text] [Related]

  • 23. Lower concentrations of thrombin-antithrombin complex (TAT) correlate to higher recanalisation rates among ischaemic stroke patients treated with t-PA.
    Fernandez-Cadenas I, Mendioroz M, Munuera J, Alvarez-Sabin J, Rovira A, Quiroga A, Corbeto N, Rubiera M, Delgado P, Rosell A, Ribó M, Molina CA, Montaner J.
    Thromb Haemost; 2009 Oct 20; 102(4):759-64. PubMed ID: 19806263
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Safety and efficacy of MRI-based selection for recombinant tissue plasminogen activator treatment: responder analysis of outcome in the 3-hour time window.
    Sølling C, Hjort N, Ashkanian M, Østergaard L, Andersen G.
    Cerebrovasc Dis; 2009 Oct 20; 27(3):223-9. PubMed ID: 19176954
    [Abstract] [Full Text] [Related]

  • 27. Hypointense transcerebral veins at T2*-weighted MRI: a marker of hemorrhagic transformation risk in patients treated with intravenous tissue plasminogen activator.
    Hermier M, Nighoghossian N, Derex L, Adeleine P, Wiart M, Berthezène Y, Cotton F, Pialat JB, Dardel P, Honnorat J, Trouillas P, Froment JC.
    J Cereb Blood Flow Metab; 2003 Nov 20; 23(11):1362-70. PubMed ID: 14600444
    [Abstract] [Full Text] [Related]

  • 28. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II).
    Larrue V, von Kummer R R, Müller A, Bluhmki E.
    Stroke; 2001 Feb 20; 32(2):438-41. PubMed ID: 11157179
    [Abstract] [Full Text] [Related]

  • 29. The time course and determinants of temperature within the first 48 h after ischaemic stroke.
    Wong AA, Davis JP, Schluter PJ, Henderson RD, O'Sullivan JD, Read SJ.
    Cerebrovasc Dis; 2007 Feb 20; 24(1):104-10. PubMed ID: 17519552
    [Abstract] [Full Text] [Related]

  • 30. Body temperature and major neurological improvement in tPA-treated stroke patients.
    Kvistad CE, Thomassen L, Waje-Andreassen U, Logallo N, Naess H.
    Acta Neurol Scand; 2014 May 20; 129(5):325-9. PubMed ID: 24111500
    [Abstract] [Full Text] [Related]

  • 31. Serum tight-junction proteins predict hemorrhagic transformation in ischemic stroke patients.
    Kazmierski R, Michalak S, Wencel-Warot A, Nowinski WL.
    Neurology; 2012 Oct 16; 79(16):1677-85. PubMed ID: 22993287
    [Abstract] [Full Text] [Related]

  • 32. The rtPA increases MMP-9 activity in serum during ischaemic stroke.
    Gołąb P, Boguszewska-Czubara A, Kiełbus M, Kurzepa J.
    Neurol Neurochir Pol; 2014 Oct 16; 48(5):309-14. PubMed ID: 25440008
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Prediction of hemorrhagic transformation in acute ischaemic stroke by micro- and macroalbuminuria after intravenous thrombolysis.
    Cho BH, Kim JT, Chang J, Choi KH, Park MS, Cho KH.
    Eur J Neurol; 2013 Aug 16; 20(8):1145-52. PubMed ID: 23582041
    [Abstract] [Full Text] [Related]

  • 35. Combined treatment with recombinant tissue plasminogen activator and dexamethasone phosphate-containing liposomes improves neurological outcome and restricts lesion progression after embolic stroke in rats.
    Tiebosch IA, Crielaard BJ, Bouts MJ, Zwartbol R, Salas-Perdomo A, Lammers T, Planas AM, Storm G, Dijkhuizen RM.
    J Neurochem; 2012 Nov 16; 123 Suppl 2():65-74. PubMed ID: 23050644
    [Abstract] [Full Text] [Related]

  • 36. Safety profile of tissue plasminogen activator treatment among stroke patients carrying a common polymorphism (C-1562T) in the promoter region of the matrix metalloproteinase-9 gene.
    Montaner J, Fernández-Cadenas I, Molina CA, Monasterio J, Arenillas JF, Ribó M, Quintana M, Chacón P, Andreu AL, Alvarez-Sabín J.
    Stroke; 2003 Dec 16; 34(12):2851-5. PubMed ID: 14605329
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Suppression of NLRP3 attenuates hemorrhagic transformation after delayed rtPA treatment in thromboembolic stroke rats: Involvement of neutrophil recruitment.
    Guo Z, Yu S, Chen X, Zheng P, Hu T, Duan Z, Liu X, Liu Q, Ye R, Zhu W, Liu X.
    Brain Res Bull; 2018 Mar 16; 137():229-240. PubMed ID: 29258866
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. High serum levels of endothelin-1 predict severe cerebral edema in patients with acute ischemic stroke treated with t-PA.
    Moldes O, Sobrino T, Millán M, Castellanos M, Pérez de la Ossa N, Leira R, Serena J, Vivancos J, Dávalos A, Castillo J.
    Stroke; 2008 Jul 16; 39(7):2006-10. PubMed ID: 18436890
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.